Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years).

摘要: Abstract Background We conducted a multicenter prospective trial to assess tolerability and activity of pegylated liposomal doxorubicin (PLD) in women ≥70years with locally-advanced or metastatic breast cancer. Patients Methods All patients underwent Multidimensional Geriatric Assessment (MGA). Frail were excluded. Normal cardiac function was required for inclusion. A bi-weekly schedule PLD at 20mg/mq adopted. Results Thirty-two enrolled median age 78years, 78.1% visceral involvement, 37.6% previously treated chemotherapy advanced disease. mean 7.8cycles delivered (range 1 20), cumulative dose intensity 8.9mg/m 2 /week. Grade 3–4 toxicities anemia (6.3%), palmar–plantar erythrodysesthesia mucositis infection (3.1%), pulmonary embolism (3.1%). No events registered. Causes treatment interruption maximal response (15.6%), progression (40.6%), refusal/loss follow-up (28.1%), (9.4%), other (6.3%). Response obtained 33.3% 27 evaluable patients; time (TTP) 10.3months. MGA status (vulnerable vs. fit) did not have an impact on response, progression, toxicity. Conclusions Bi-weekly is well tolerated both fit vulnerable patients, apparently fairly good rate TTP (possibly biased by subsequent endocrine therapy loss follow-up). Close observation recommended order avoid early follow-up.